Mitochondrial-Targeted Molecular Imaging in Cardiac Disease

Li, Jinhui; Lu, Jing; Zhou, You

doi:10.1155/2017/5246853

Cited by 14 publications

(11 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MitoTimer enables the study of mitochondrial structure, redox state, and mitophagic disposal by fluorescence microscopy on fixed tissue 326,327 . Finally, multiple radioactive tracers are being developed to monitor mitochondrial functions in real time in the setting of CVD 26,328 . These molecules, some of which are already approved for use in humans (for different applications), might constitute preferential tools to study the links between mitochondrial dysfunction and multiple forms of CVD in patients.…”

Section: Obstacles In the Development Of Mtasmentioning

confidence: 99%

Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles

et al. 2018

View full text Add to dashboard Cite

A large body of evidence indicates that mitochondrial dysfunction has a major role in the pathogenesis of multiple cardiovascular disorders. Over the past 2 decades, extraordinary efforts have been focused on the development of agents that specifically target mitochondria for the treatment of cardiovascular disease. Despite such an intensive wave of investigation, no drugs specifically conceived to modulate mitochondrial functions are currently available for the clinical management of cardiovascular disease. In this Review, we discuss the therapeutic potential of targeting mitochondria in patients with cardiovascular disease, examine the obstacles that have restrained the development of mitochondria-targeting agents thus far, and identify strategies that might empower the full clinical potential of this approach.

show abstract

Section: Obstacles In the Development Of Mtasmentioning

confidence: 99%

Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles

et al. 2018

View full text Add to dashboard Cite

show abstract

“…By contrast, a relatively large number of imaging studies have been reported with mitochondria-tropic radioprobes, mainly for in vivo tumor detection. This included several lipophilic cations originally developed for myocardial perfusion SPECT imaging, such as the cardiac agent 99m Tc-MIBI ( 99m Tc-Sestamibi) or the 99m Tc-TMEOP complex introduced by our group [ 14 , 15 , 16 , 17 , 18 ]. Among the mitochondrial-targeting moieties, the most widely applied is triphenylphosphonium (TPP), which is a delocalized cationic lipid that readily penetrates through the mitochondrial membrane due to the highly negative mitochondrial membrane potential [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Biological Evaluation of 99mTc(I) Tricarbonyl Complexes Dual-Targeted at Tumoral Mitochondria

et al. 2021

View full text Add to dashboard Cite

For effective Auger therapy of cancer, the Auger-electron emitters must be delivered to the tumor cells in close proximity to a radiosensitive cellular target. Nuclear DNA is considered the most relevant target of Auger electrons to have augmented radiotoxic effects and significant cell death. However, there is a growing body of evidence that other targets, such as the mitochondria, could be relevant subcellular targets in Auger therapy. Thus, we developed dual-targeted 99mTc(I) tricarbonyl complexes containing a triphenylphosphonium (TPP) moiety to promote accumulation of 99mTc in the mitochondria, and a bombesin peptide to provide specificity towards the gastrin releasing peptide receptor (GRPr) overexpressed in prostate cancer cells. The designed dual-targeted complex, 99mTc-TPP-BBN, is efficiently internalized by human prostate cancer PC3 cells through a specific GRPr-mediated mechanism of uptake. Moreover, the radioconjugate provided an augmented accumulation of 99mTc in the mitochondria of the target tumor cells, most probably following its intracellular cleavage by cathepsin B. In addition, 99mTc-TPP-BBN showed an enhanced ability to reduce the survival of PC3 cells, in a dose-dependent manner.

show abstract

“…Therefore, G-MPI can show abnormal local myocardial perfusion, which can be used for early noninvasive evaluation of abnormal changes in mitochondrial function of cardiomyocytes [43][44][45].…”

Section: Discussionmentioning

confidence: 99%

Summed rest score in gated myocardial perfusion imaging is a good predicator for treatment-related cardiotoxicity after anthracycline chemotherapy in diffuse large B-cell lymphoma patients

Yang¹,

Wang²,

Xu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Anthracycline chemotherapy is commonly used in the treatment of diffuse large B-cell lymphoma (DLBCL) patients. Treatment-related cardiotoxicity (TRC) may be observed during treatment and may induce severe cardiac failure or cardiac arrhythmia as the main cause of death, even several years after chemotherapy implementation. Herein, we performed a study to investigate the prognostic value of gated myocardial perfusion imaging (G-MPI) summed rest score (SRS) for the early detection of TRC caused by anthracycline chemotherapy in DLBCL patients.Methods: A total of 36 DLBCL patients were enrolled, and a series of parameters from the same individual patient were compared between baseline and after the end of the 6th R-CHOP chemotherapeutic regimen. According to whether TRC occurred during the observation period, the patients were divided into two groups, and parameters related to cardiac function were compared.Results: SRS in G-MPI and QTc interval in electrocardiogram were significantly different before and after chemotherapy (P = 0.012 and P = 0.015, respectively).By comparing parameters related to cardiac function between the TRC group (n = 22) and the no-TRC group (n = 14), only SRS was significantly different (P = 0.012). Multivariate logistic regression analysis showed that the SRS level was the only independent predicator for TRC (P = 0.018, HR = 6.053, 95% CI: 1.364-26.869). Receiver operating characteristic curve analysis identified an optimal SRS cutoff of >1for predicting TRC after anthracycline chemotherapy (P＜ 0.001).Conclusion: The G-MPI SRS level was an early indicator for TRC surveillance in DLBCL patients after anthracycline chemotherapy, thus contributing to early treatment and a subsequent decrease in mortality caused by such cardiovascular complications.

show abstract

Mitochondrial-Targeted Molecular Imaging in Cardiac Disease

Cited by 14 publications

References 92 publications

Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles

Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles

Synthesis and Biological Evaluation of 99mTc(I) Tricarbonyl Complexes Dual-Targeted at Tumoral Mitochondria

Summed rest score in gated myocardial perfusion imaging is a good predicator for treatment-related cardiotoxicity after anthracycline chemotherapy in diffuse large B-cell lymphoma patients

Contact Info

Product

Resources

About